

# Keystone Symposia: Alzheimer's Disease Beyond A $\beta$

Sponsored by Schering-Plough Research Institute

January 10–15, 2010 • Copper Mountain Resort • Copper Mountain, Colorado • USA

Scientific Organizers: JoAnne McLaurin and Tony Wyss-Coray

## PROGRAM FACULTY & TALKS

**Ottavio Arancio**, Columbia University Medical Center, USA

*Amyloid-beta: From Physiology to Pathology*

**Steffany A.L. Bennett**, University of Ottawa, Canada

*Phospholipid Mediators of Synaptic Dysfunction*

**Roxana Octavia Carare**, University of Southampton, UK

*Failure of Elimination of A $\beta$  along Perivascular Pathways and the Etiology of Alzheimer's Disease*

**Bart De Strooper**, Center for Human Genetics, Belgium

*RNAi Approaches to Understanding and Treating Alzheimer's Disease*

**Joseph El Khoury**, Massachusetts General Hospital, USA

*Cell Recruitment*

**Dora Games\***, Elan Pharmaceuticals, USA

*Issues and Advances in the Development of Immunotherapeutic Approaches for Alzheimer's Disease*

**Todd Eliot Golde**, Mayo Clinic Jacksonville, USA

*Preclinical Studies of Alzheimer's Disease and the Treatment versus Prevention Paradox*

**Franz F. Hefti**, Avid Radiopharmaceuticals, Inc., USA

*PET Radiopharmaceuticals for Diagnosis of Dementias*

**Michael Hutton**, Merck & Co., Inc., USA

*Tau-Based Drug Discovery in Alzheimer's Disease*

**Kullervo Hynynen**, Sunnybrook Health Sciences Centre, Canada

*MRI Guided Ultrasound Delivery of Drugs to the CNS*

**William J. Jagust**, University of California, Berkeley, USA

*Structural and Neurochemical Changes within the CNS during Aging and Alzheimer's Disease*

**Sheena Josselyn**, Hospital for Sick Children, Canada

*Cognitive Deficits in a Mouse Model of Alzheimer's Disease: The Role of CREB*

**Jeffery W. Kelly**, The Scripps Research Institute, USA

*Restoring Protein Homeostasis*

**Peter T. Lansbury**, Harvard Medical School / Link Medicine, USA

*A New Therapeutic Strategy for Neurodegeneration*

**Susan L. Lindquist**, Whitehead Institute for Biomedical Research, USA

*Protein Aggregation*

**Frank Longo**, Stanford School of Medicine, USA

*Small Molecule p75 Receptor Ligands Inhibit A $\beta$ -Induced Degeneration, Synaptic Dysfunction and Cognitive Loss*

**JoAnne McLaurin**, University of Toronto, Canada

*Small Molecule Therapy for Alzheimer's Disease*

**Lennart Mucke\***, University of California, San Francisco, USA

*Strategies to Block A $\beta$ -Induced Neuronal Dysfunction*

**Steven M. Paul**, Eli Lilly and Company, USA

*Overview*

**Daniel A. Peterson**, Rosalind Franklin University, Chicago Medical School, USA

*The Contribution of Neurogenesis in Repairing the Aging Brain*

**Josef Priller**, Charité – Universitätsmedizin Berlin, Germany

*Bone Marrow-Derived Cells in Alzheimer's Disease*

**Richard M. Ransohoff**, Cleveland Clinic, USA

*Microglia, Monocytes and Macrophages*

**Holly Soares**, Pfizer Inc., USA

*Multiplex Panels as Diagnostic Tools in Alzheimer's Disease*

**Stephen M. Strittmatter**, Yale University, USA

*Receptors for Degeneration and Regeneration in Alzheimer's Disease*

**Marc Tessier-Lavigne**, Genentech, Inc., USA

*APP-DR6 Signaling in Development and Degeneration*

**Terrence Town**, Cedars-Sinai Medical Center, USA

*Innate Immunity and Alzheimer's Disease*

**Tony Wyss-Coray**, Stanford University School of Medicine, USA

*The Plasma Communicome of Normal Aging and Dementia*

**Zhenyu Yue**, Mount Sinai School of Medicine, USA

*Autophagy and Neurodegeneration*



By 2010 many of the clinical trials presently underway targeting A $\beta$  will have been completed or far enough along the pathway that we will have a better understanding of the benefit and limitations of this approach. This leads us to consider what are the next targets that will need to be addressed to fully treat and prevent Alzheimer's disease. The objective of this meeting is therefore to stimulate and promote a discussion beyond A $\beta$  as a key factor and therapeutic target in Alzheimer's disease. This objective will be equally important whether therapeutic approaches targeting A $\beta$  are successful or not, to either complement and expand successful A $\beta$  therapies or to initiate a paradigm shift. In particular, we would like to discuss the generation of alternative models to study Alzheimer's disease, and highlight several exciting areas of research including the role of synaptic dysfunction, neuronal regeneration, the immune system and protein degradation in Alzheimer's disease.

## PROGRAM PLENARY SESSIONS:

- Remodeling Alzheimer's Disease: An Academic Perspective
- Remodeling Alzheimer's Disease II: An Industry Perspective
- Alzheimer's and Synaptic/Neuronal Dysfunction
- Alzheimer's Disease and Neuronal Regeneration
- Alzheimer's and the Immune System
- Alzheimer's and Protein Degradation
- Alzheimer's Disease and Diagnostics
- Alzheimer's Disease and Therapeutics

## DEADLINES:

Abstract & Scholarship: September 15, 2009

Late-Breaking Abstract: October 13, 2009

Early Registration: November 10, 2009

[www.keystonesymposia.org/10A4](http://www.keystonesymposia.org/10A4)

KEYSTONE  SYMPOSIA™  
on Molecular and Cellular Biology  
Accelerating Life Science Discovery

PO Box 1630 • Silverthorne, CO 80498 • USA  
[www.keystonesymposia.org](http://www.keystonesymposia.org) • 1-800-253-0685 • 1-970-262-1230

\*Keynote speaker. Program subject to change. Current as of September 8, 2009